50 results about "Cell soma" patented technology

The invention relates to the technical field of biology, in particular to a Treg cell amplification culture medium and a preparation method of Treg cells. According to the method for in-vitro amplification of the regulatory T cells (Treg) from peripheral blood, the amplification efficiency and purity of the Treg cells are improved, the culture cost is reduced, the culture period is shortened, and the problem of trophoblast cell residues in subsequent clinical application is solved.

The application discloses a kind of multiple immunofluorescence detection method, equipment and medium based on space reconstruction, it is related to histopathological analysis technical field, including, preparation tissue sample and join fluorescent reference microbead to obtain continuous section;To the tissue sample cycle pretreatment, and utilize fluorescent reference microbead to carry out intensity normalization and bleaching time shift correction, obtain correction image sequence;Spectral unmixing is carried out under three-dimensional voxel coordinate system and introduces space regular constraint, obtain voxel level fluorescence intensity vector;Combining nuclear dye signal and fluorescent reference microbead, using rigid and non-rigid registration and supplemented with three-dimensional deconvolution, reconstruct high-resolution voxel stack and segment cell voxel set;The adjacent relationship and colocalization index of different phenotype cells are calculated, and detection result is generated.The application realizes high-resolution tissue and cell reconstruction under three-dimensional space, improves spatial continuity and accuracy, and improves the stability and accuracy of voxel level fluorescence signal quantification.

The application relates to the technical field of cell in-vitro culture, and discloses a sphincter in-vitro culture environment construction device which comprises a culture device and a control host computer, the culture device is internally provided with a contraction member, the control host computer is connected with the culture device in a matched mode, and is used for regulating and controlling the action of the contraction member, so as to construct a physiological contraction environment. The application can simulate the annular contraction and the physiological contraction characteristics of the high and low pressure of the human sphincter, restore the dynamic contraction process, adopt a detachable structure, adapt to different culture cavities, has strong experimental flexibility, combines a perfusion design with a three-dimensional culture layer, simulates in-vivo nutrition transportation and metabolism discharge, provides a bionic growth environment for cells, integrates strain force detection and temperature control closed-loop regulation, is accurate in parameters and reliable in data, makes up for the short board of traditional static culture and animal experiments, provides a stable and efficient experimental platform for sphincter disease mechanism, mechanical response research and drug screening.

The invention belongs to the technical field of biological medicine research, and particularly relates to a cell in-vitro calcification inducer, an induction culture medium and application thereof, an aortic valve calcification in-vitro induction model and a modeling method thereof. The inducer provided by the invention is prepared from the following components in parts by weight: 2160.4 parts of beta-sodium glycerophosphate, 0.039 parts of dexamethasone, 50 parts of vitamin C and 34 parts of vitamin D. The invention further provides a culture medium formed by using the inducer and a method for modeling an aortic valve calcification in-vitro induction model by using the inducer. According to the method, osteogenic differentiation of the aortic valve interstitial cells can be stably induced within a short time, an efficient and repeatable standardized induction scheme is provided for in-vitro aortic valve calcification models and drug screening, and the method has a very good application prospect.

The invention relates to application of lentinan in preparation of a medicine for enhancing Kukuzhou cell immune function, and belongs to the technical field of immunopharmacology. The invention discloses a mechanism and application of lentinan LNT (Lentinan) based on a TLR2 (Toll-Liver Receptor 2) signal channel for enhancing the immune function of liver cumness cells and promoting lysosome maturation. By constructing an LNT fluorescence labeling system, a Kuptake cell in-vivo tracing model and a TLR2 function intervention model, it is proved that LNT can be directly combined with TLR2 and activate a TLR2 / MyD88 / NF-kappa B signal axis, and therefore the phagocytosis and immune response capacity of Kuptake cells is enhanced. Meanwhile, TLR2 signal-induced reactive oxygen species (ROS) up-regulation can promote TFEB dephosphorylation and nuclear translocation, lysosome maturation is driven, and degradation metabolism of LNT is accelerated. The invention provides a TLR2-based immune enhancement mechanism of the LNT, and provides a theoretical basis and an application basis for developing immunomodulatory targeted drugs.

The present disclosure provides compositions, kits, and methods for promoting in vitro maturation of cells. The compositions, kits, and methods utilize at least one inhibitor of an epigenetic regulator and at least one agonist of a calcium channel. Suitable applications of the present disclosure include use in maturing and differentiation stem cells into viable mature neuronal cells for use in disease modeling, prevention and treatment. The present disclosure also provides methods of screening compounds that are suitable for promoting in vitro maturation of cells.

The application relates to a G-quadruplex RNA fluorescent ligand and a preparation method and application thereof, a structure formula of the G-quadruplex RNA fluorescent ligand is shown in the following formula: the compound can be specifically targeted and can be subjected to fluorescent imaging in a solution system and a cell system, a high-throughput fluorescent screening method is established in the solution and the cell system, and an organic small-molecule compound with strong binding capacity to G-quadruplex RNA can be effectively identified and screened from a small-molecule drug library; the screening result of the method is high in accuracy, the affinity and biological activity of a candidate compound can be quickly determined by evaluating the change of a fluorescent signal, and therefore the research and development process of an antitumor drug is accelerated; and the application belongs to the field of biological medicines.

The invention provides an extraction method of high-performance gamma delta T immune cells and application of the high-performance gamma delta T immune cells in tumors. The method comprises the following steps: firstly, separating mononuclear cells from peripheral blood, carrying out activation induction by using a serum-free culture medium containing zoledronic acid, IL-15 and OKT3, and supplementing a culture medium containing IL-2 according to a specific proportion for multiplication culture from the third day of culture. Through the optimization process, the expression rate of TCR-gamma delta < + > is as high as 96.84%, and gamma delta T cells with high activity are obtained. An in-vivo tumor inhibition experiment shows that the cell has a remarkable growth inhibition effect on liver cancer nude mouse transplanted tumor, the effect is equivalent to that of a positive control drug, and obvious toxic and side effects are not observed. The method is stable in process and clear in component, and a reliable technical basis is provided for clinical transformation of gamma delta T cells in immunotherapy of solid tumors and hematologic tumors.

The invention belongs to the technical field of cell therapy, and relates to a serum-free and heterologous component-free NK cell culture medium as well as a preparation method and application thereof. The culture medium comprises a classical culture medium, a proliferation promoting component, vitamins, trace elements, lipids, transferrin, an energy substance and beta-mercaptoethanol, the proliferation promoting component is prepared from human albumin, resveratrol, insulin and hydroxyproline. On the basis of a serum-free and heterologous component-free NK cell culture medium, IL-12, rapamycin, polyinosinic-polycytidylic acid and human AB plasma are additionally added to obtain an activated culture medium, the activated culture medium and an amplification culture medium are jointly used, the culture effect is better, and amplification components IL-2 and human AB plasma are additionally added to obtain an amplification culture medium. Through precise component design, the NK cell in-vitro proliferation efficiency, motility, purity and killing ability are remarkably improved, and key problems existing in a traditional culture medium are efficiently solved.

The application discloses a kind of mixed immune cells and its culture system and in vitro culture method.The mixed immune cells include 75%~80% of γδT cell, 10%~15% of NK cell and 1~2% of NKT cell.The in vitro culture method of the application includes, when peripheral blood mononuclear cell is inoculated with activation culture medium, adding immune cell first activation component, adding immune cell reactivation component after 0~6 hours of inoculation, continuous activation culture;Then the activated culture cell is transferred into the coated culture plate or culture bottle, and the mixed immune cell is obtained by expansion culture.The mixed immune cell of the application has higher liver cancer cell HepG2 killing effect.The mixed immune cell in vitro culture method of the application has high expansion efficiency, and the expansion multiple can reach 2000-8000 times.

The invention provides a culture medium and an in-vitro induction method for in-vitro erythroid induction of trace primary erythroid terminally differentiated cells, and belongs to the technical field of erythrocyte induction. The invention provides a culture medium for inducing primary erythroid terminal differentiated cells into erythrocytes in vitro. The culture medium comprises a first culture medium added with a plurality of inducing factors and a second culture medium not added with the inducing factors. The invention also develops a method for inducing micro primary erythroid terminal differentiated cells into erythrocytes in vitro, the method is suitable for primary cells, and the problem of drug response distortion caused by large difference between an immortalized cell line and cells in a living body is effectively avoided. According to the in-vitro induction method disclosed by the invention, the maturing and differentiating process can be completed in vitro only by using a very small amount of primary cells, so that the dependence on precious clinical samples is greatly reduced, and repeated experiments and high-throughput screening by using limited samples become possible.

Methods of treating diseases associated with pathologic neuronal cells are provided. Accordingly, there is provided a method of treating a disease associated with pathologic neuronal cells characterized by aberrant excitability comprising: (a) administering into a first neural region of the subject a therapeutically effective amount of a polynucleotide encoding a bistable type II opsin attached to a heterologous ER export signal and / or membrane trafficking signal which enables trafficking of said bistable type II opsin to axon and / or dendrite terminals, wherein said first neural region comprises cell bodies of said pathologic neuronal cells; and (b) exposing a second neural region of said subject to light in a wavelength that activates said bistable type II opsin, wherein said second neural region comprises axon or dendrite terminals of said pathologic neuronal cells associated with a symptom of said disease, and wherein said first neural region and said second neural region are distinct.

The application discloses a Turn-Off type cell in-vivo tracing probe and a preparation method and application thereof, and the probe structure is composed of three parts, including a membrane anchoring part, an enzyme specificity response part and a fluorescent group. The probe can mark cells through the hydrophobic tail chain of the membrane anchoring part, at this time, the fluorescent group part emits near-infrared fluorescence, and shows a Turn state. When the adoptive cells are apoptotic in the body, the probe falls off from the cells. The free probe falling off is phagocytosed by macrophages in the body, in the intracellular macrophages, the enzyme specificity response part in the probe structure responds to enzyme bond breaking, the fluorescent group is dissociated, does not emit light, and shows an Off state. Therefore, the fluorescent probe can not only trace the in-vivo living cells and monitor the death and life of the cells in the body, but also can effectively overcome the fluorescent "pollution" phenomenon caused by the persistent existence of the fluorescent of the free probe falling off, and provides a new visual tool for monitoring the in-vivo fate of the living cell drugs.

The application discloses application of ostruthin in enhancing CAR-T cell anti-tumor function, belongs to the technical field of biological medicine, and the ostruthin can promote cell proliferation, inhibit cell exhaustion, promote the secretion of cytokines related to killing cancer cells, and further enhance the anti-tumor function of CAR-T cells in vivo and in vitro as a cell enhancer of CAR-T cells; experimental results show that when ostruthin is combined with CAR-T cells for anti-tumor treatment, compared with ostruthin or CAR-T cells alone, the combination of the two can significantly inhibit the growth of solid tumors. The application provides a new technical means for improving the tumor treatment effect of CAR-T cell immunotherapy.

The application provides a method for enhancing the expansion and activation of memory-like NK cells, and belongs to the technical field of cell culture. The application provides a method for obtaining strong memory-like NK cells, which comprises using complete culture medium, IL-2, IL-12, IL-15, IL-18, sodium alpha-ketoglutarate and DOT1L inhibitor; the concentration of the sodium alpha-ketoglutarate is 0.1-2 mM, and the concentration of the DOT1L inhibitor is 10-100 nM. The addition of low-concentration sodium alpha-ketoglutarate in the complete culture medium of memory-like NK cells can promote the in-vivo and in-vitro proliferation capacity of the memory-like NK cells. The addition of low-concentration DOT1L inhibitor in the late culture stage can further enhance the killing function of the memory-like NK cells by inhibiting H3K79me2 / 3, etc., so that memory-like NK cells with a larger number and stronger killing capacity are obtained.

The application discloses a culture medium and application thereof, and a method for in-vitro separation and culture of goat intramuscular precursor fat cells and adipogenic differentiation of the cells, and relates to the technical field of cell culture. The culture medium comprises the following components: 8-12 mu g / mL insulin, 8-12% fetal bovine serum in volume fraction, 95-105 U / mL penicillin, 95-105 mu g / mL streptomycin, and the like. On the basis of the prior art, the application mainly adds appropriate glycyrrhizin and pilocarpine in the culture medium, and finds that the two components are in cooperation, and the adipogenic differentiation ability of cells such as mesenchymal stem cells and precursor fat cells is significantly improved, and the application range is wide. On the basis, the application further provides a complete method for in-vitro separation and culture of goat intramuscular precursor fat cells and adipogenic differentiation of the cells, and provides a method and a way for a series of researches on goat primary intramuscular precursor fat cells in the future.

This invention discloses the application of T cells overexpressing PRDM16 in the preparation of anti-tumor or infectious disease drugs. Through experiments, this invention verifies that overexpression of PRDM16 enhances the in vivo and in vitro activity of T cells. It was found that in vitro overexpression of PRDM16 significantly enhances the killing effect of T cells on target cells. In vivo reinfusion of PRDM16 has stronger anti-tumor and anti-infection functions compared to wild-type T cells. Therefore, it can be used in malignant tumors and infectious diseases to enhance the efficacy of T cell adoptive therapy and solve the defect of T cell adoptive therapy where the killing power of target cells is suppressed due to environmental influences.

The present disclosure provides a method of generating CD4-CD8 + T cells in vitro from hematopoietic stem / progenitor cells. Cell populations produced using the methods and methods of using the cell populations are provided.

The application discloses an integrated in-situ observation carrier table cell culture device, which comprises a surrounding containing mechanism, a cell carrier, a stress loading mechanism and a control circuit board. The application also discloses an environment control method based on the integrated in-situ observation carrier table cell culture device. The integrated in-situ observation carrier table cell culture device and the environment control method are used for cell in-vitro culture and can realize in-situ real-time microscopic observation of cells, and realize multi-stage regulation of gas and temperature in the integrated in-situ observation carrier table cell culture device. The heat distribution and the uniform distribution of gas concentration are realized through the internal mixing, internal circulation and external circulation integrated method. The application has the characteristics of high portability, high integration, convenient operation, high flexibility, low cost and multiple functions.

The invention provides a preparation method of a PD-1 + T cell and application of the PD-1 + T cell in PD-1 antibody drug-resistant solid tumor treatment, and belongs to the technical field of biomedicine, and the preparation method comprises the step of preparing the PD-1 + T cell by taking peripheral blood of a patient as a raw material. The problems that traditional ILs are difficult to draw, the in-vitro amplification efficiency of the PD-1 + T cells is low, and functions are prone to being lost are solved, meanwhile, the application of the PD-1 + T cells in treatment of PD-1 antibody drug-resistant solid tumors is provided, and the blank of follow-up treatment of PD-1 antibody drug-resistant patients is filled.

Disclosed is a method for in vitro expansion of tumor-infiltrating lymphocytes. Developed are a new method for isolating and enriching TIL cells in tumor tissues and an optimized culture method for TIL cells independent of feeder cells. 1010 grade or more of TIL cells having an anti-tumor function can be obtained. By means of cell phenotype analysis, compared with TILs expanded by the traditional two-step method, the cultured TIL cells have a higher proportion of memory T cells and a lower proportion of exhausted T cells and regulatory T cells.

The invention belongs to the technical field of tumor cell treatment, and particularly relates to a serum-free culture medium for improving the function and durability of CAR-T cells and reversing depletion and application of the serum-free culture medium. According to the serum-free culture medium, low-concentration statins are added into a conventional culture medium of T cells. The invention further provides in-vitro preparation of the serum-free culture medium in CAR-T cells and application of the serum-free culture medium in reduction of CAR-T cell depletion, maintenance of a low differentiation state of the CAR-T cells, promotion of metabolic adaptability of the CAR-T cells and improvement of the anti-tumor function of the CAR-T cells.

The invention discloses application of thiamine pyrophosphoric acid in enhancing the anti-tumor function of T cells and CAR-T cells, and belongs to the technical field of biomedicine.The thiamine pyrophosphoric acid serving as a cell enhancer of the T cells and the CAR-T cells can promote cell proliferation, inhibit cell depletion and promote cells to secrete cytokines related to killing cancer cells at the same time, and the anti-tumor function of the T cells and the CAR-T cells is enhanced. Further, the in-vivo and in-vitro anti-tumor functions of the T cells and the CAR-T cells can be enhanced; experimental results show that when the thiamine pyrophosphate is combined with the T cell or the CAR-T cell to carry out anti-tumor treatment, compared with independent use of the T cell or the CAR-T cell, the combined application of the thiamine pyrophosphate and the T cell or the CAR-T cell can obviously inhibit the growth of various solid tumors. The invention provides a new strategy for improving cell immunotherapy based on T cells or CAR-T cells.

The invention relates to the field of cell engineering, and particularly discloses a preparation method and application of a conditionally immortalized human myocardial fibroblast model. According to the method, a Tet-on system driven by a cardiac fibroblast specific promoter is constructed to regulate and control a lentiviral vector of an SV40LT-tsA58 temperature-sensitive mutant gene, and after primary human cardiac fibroblasts are transduced, conditional immortalization of the cells is realized in the presence of an inducer doxycycline. The model can be stably amplified under an induction condition, the immortalized gene expression is closed after an inducer is removed, the primary physiological state of cells is recovered, and the high-fidelity response capability to fibrosis promoting and anti-fibrosis drugs is reserved. According to the method, the in-vitro proliferation limit of primary cells is broken through, the problems of species difference and ethics are avoided, and a humanized, high-fidelity and high-controllability standardized tool is provided for myocardial fibrosis pathological mechanism research and drug screening.

To provide a method for stabilizing and isolating a plurality of biological targets contained in a cell-containing body fluid.SOLUTION: (A) providing a stabilized cell-containing body fluid sample by contacting a cell-containing body fluid with a stabilizing composition comprising one or more of the following stabilizing factors: (a) at least one primary, secondary or tertiary amide, (b) at least one poly (oxyethylene) polymer, and / or (c) at least one apoptosis inhibitor, (B) maintaining the stabilized cell-containing body fluid sample for a stabilization period, (C) determining the presence or absence of a cell subpopulation, extracellular nucleic acids, extracellular vesicles, and treating the stabilized cell-containing body fluid sample to enrich three or more biological targets selected from the group consisting of intracellular nucleic acids from the stabilized cell-containing body fluid. The method allows for multimodal analysis of different biological targets from a single stabilized cell-containing body fluid sample.SELECTED DRAWING: None

Disclosed are various embodiments for growing, culturing, monitoring, and analyzing embryoid bodies, fused embryoid bodies, spheroids, organoids, or other multi-cellular bodies using a system of microplates. Different types of microplates are designed to be used during the various stages of growing and culturing of cells to form embryoid bodies, fused embryoid bodies, spheroids, organoids, or other multi-cellular bodies. The different microplates are designed to mate with one another to allow for the transfer of cells from wells in one plate to wells in the other plate. An assay plate includes an array of perfusable units that include a supply well that is in fluid communication with a culture well to allow for an exchange of fluid.

The invention relates to the technical field of marine organisms, in particular to a nucleic acid aptamer modified nerve extracellular vesicle and application thereof in prevention and treatment of marine guanamine neurotoxin poisoning. According to the invention, extracellular vesicles (nEVs) and a nucleic acid aptamer (Apt) of tetrodotoxin (TTX) are coupled to construct a guanamine toxoid nano antagonism system Apt-nEVs. According to the present invention, the Apt-nEVs retains the natural Na < + > channel on the nerve cell membrane, can synergistically provide the dual detoxification function of the coupling aptamer and the natural Na < + > channel to identify and trap TTX, can achieve the efficient detoxification of TTX in the non-cell system and the cell level, and can significantly protect the cell oxidative stress injury caused by TTX. In addition, the aptamer coupled extracellular vesicles (Apt-nEVs) obtained in the invention can also provide thought and reference for construction of a more broad-spectrum marine biotoxin antagonism system.

This invention relates to a brain-targeting nanomedicine formulation for glioblastoma and its preparation method, belonging to the field of pharmaceutical technology. The formulation comprises an active pharmaceutical ingredient, an amphiphilic block copolymer carrier, a covalently bonded brain-targeting ligand, and a stabilizer. The preparation method includes: chemically coupling the targeting ligand to the carrier material; self-assembling the drug, modified carrier, and stabilizer into nanoparticles using a nanoprecipitation method; and obtaining the final product through membrane extrusion granulation, purification, and lyophilization. The resulting nanoparticles have uniform particle size, high drug loading, and good stability, and can simultaneously achieve efficient crossing of the blood-brain barrier and specific targeting of glioma cells. In vitro and in vivo experiments show that this formulation can significantly improve drug accumulation at brain tumor sites, inhibit tumor growth, and prolong the survival of model animals. Furthermore, the preparation process is controllable and easily scaled up.

The application belongs to the technical field of medicine, and particularly relates to a CAR-gammadelta T cell targeting GP350 and a preparation method and application thereof. The application provides an antibody or antigen binding fragment thereof targeting GP350. The GP350-targeting antibody screened is used as an antigen binding domain to construct a chimeric antigen receptor, and a gammadelta T cell isolated from peripheral blood of a healthy donor is used to prepare a CAR-gammadelta T cell targeting GP350. In-vivo and in-vitro experiments show that the CAR-gammadelta T cell targeting GP350 has obvious killing activity on an EBV-positive nasopharyngeal carcinoma cell (GP350 + ). The application can be applied to the diagnosis of EBV-positive diseases, and has a broad prospect in the preparation of products for detecting, preventing and / or treating GP350-positive tumors.

This invention relates to a bilayer composite CAR-T cell in vivo delivery scaffold and its application. The in vivo delivery scaffold comprises an inner layer and an outer layer. The inner layer comprises a methacrylated hydrogel and δ-MnO2 nanosheets and cytokine 1 linked thereto. The outer layer comprises a composite hydrogel and cytokine 2 linked thereto. The composite hydrogel comprises hyaluronic acid and methacrylated gelatin. This bilayer scaffold achieves a synergistic system for structured immune induction and functional signal maintenance. The outer lymphoid-inducible matrix constructs a spatial framework for immune cell communication and memory formation, and delivers nutritional support to the inner layer. The inner oxygen-cytokine complex system maintains CAR-T cell activity and metabolic homeostasis. The synergy of these two layers can form a locally sustainable artificial immune microecology for immune activation and memory maintenance, providing a novel material basis for the long-term effectiveness and safety of CAR-T cell therapy in solid tumors.